雲頂新耀(01952.HK)旗下BL/BLI抗菌藥物或獲納入優先審評品種
雲頂新耀(01952.HK)公布,國家藥監局藥品審評中心近日公示,擬將產品Cefepime-Taniborbactam納入優先審評,用於治療包括腎盂腎炎的成人複雜性尿路感染(cUTI)。
該產品是一種BL/BLI抗菌藥物,正在開發其作為潛在治療選擇針對由抗菌藥物耐藥的革蘭陰性菌引起的嚴重細菌感染。雲頂新耀通過與Venatorx Pharmaceuticals的合作共同開發該產品,擁有在大中華區、南韓和部分東南亞國家進行開發和商業化的權益。
雲頂新耀首席執行官羅永慶表示,將與藥監部門密切溝通,盡快將該款創新抗菌藥物帶給國內患者,預期將進一步奠定公司在抗感染領域的領先地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.